IMV Inc. (TSE:IMV) Given Average Rating of “Moderate Buy” by Analysts

Shares of IMV Inc. (TSE:IMVGet Rating) have been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is C$5.31.

A number of equities analysts have recently weighed in on IMV shares. HC Wainwright reaffirmed a “buy” rating and set a C$13.00 target price on shares of IMV in a research report on Wednesday, June 22nd. Echelon Wealth Partners restated a “buy” rating on shares of IMV in a research note on Friday, May 13th.

IMV Price Performance

IMV opened at C$0.65 on Monday. IMV has a fifty-two week low of C$0.60 and a fifty-two week high of C$3.00. The company has a debt-to-equity ratio of 170.58, a quick ratio of 3.27 and a current ratio of 3.85. The company has a market capitalization of C$53.54 million and a P/E ratio of -0.97. The stock has a fifty day moving average of C$0.87 and a 200-day moving average of C$1.32.

IMV (TSE:IMVGet Rating) last released its quarterly earnings results on Friday, May 13th. The company reported C($0.16) earnings per share for the quarter, topping the consensus estimate of C($0.19) by C$0.03. The firm had revenue of C$0.03 million for the quarter. On average, equities analysts expect that IMV will post -0.57 EPS for the current year.

About IMV

(Get Rating)

IMV Inc operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer.

Read More

Analyst Recommendations for IMV (TSE:IMV)

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with's FREE daily email newsletter.